TACE联合纳米粒治疗早期肝癌并发门静脉高压的疗效及安全性

肝脏 ›› 2021, Vol. 26 ›› Issue (1): 51-54.

TACE联合纳米粒治疗早期肝癌并发门静脉高压的疗效及安全性

房启楼, 倪建勋, 范红星, 金戈

123000 辽宁健康产业集团阜新矿总医院普外二科(房启楼,倪建勋,范红星);沈阳医学院药理办公室(金戈)

收稿日期:2020-04-02 出版日期:2021-01-31 发布日期:2021-02-26
通讯作者: 金戈,Email:jinge1026@163.com
基金资助:
辽宁省自然科学基金指导计划(20170540880)

Efficacy and safety of TACE and nanoparticles in the treatment of portal hypertension in early-stage liver cancer

FANG Qi-lou¹, NI Jian-xun¹, FAN Hong-xing¹, JIN Ge²

1. Department of General Surgery, Liaoning Health Industry Group Fuxin Mine General Hospital, Fuxin 123000,China;
2. Department of Pharmacology, Shenyang Medical College, Liaoning 110000, China

Received:2020-04-02 Online:2021-01-31 Published:2021-02-26
Contact: JIN Ge,Email:jinge1026@163.com

摘要/Abstract

摘要： 目的探究经导管肝动脉化疗栓塞(TACE)联合纳米粒在治疗早期肝癌并发门静脉高压中的临床疗效及安全性。方法选择2013年2月至2018年1月于阜新矿总医院接受治疗的98例早期肝癌并发门静脉高压患者为研究对象,其中TACE组45例,TACE联合纳米粒治疗组53例,对比两组患者治疗效果以及癌症复发率,患者术前和术后1个月肝功能及肿瘤因子指标,以及两组患者术后各类并发症发生率。结果联合组疾病客观缓解率(ORR)为58.49%(31/53),疾病控制率(DCR)为86.79%(46/53),TACE组ORR为55.56%(25/45),DCR为84.44%(38/45),差异均无统计学意义(均P>0.05)。术前和术后1个月两组患者ALT、AST、癌胚抗原(CEA)水平比对差异无统计学意义(P>0.05)。但术后1个月时联合组血管内皮生长因子(VEGF)水平为(178.89±8.65) pg/mL,低于TACE组的(211.27±7.98) pg/mL,差异有统计学意义(P<0.05)。术后1年及2年联合组复发率均低于TACE组(P<0.05)。术后并发症比较两组差异不大(P>0.05)。结论 TACE术对早期肝癌并发门静脉高压中具有较好的治疗效果,如加用纳米粒治疗能够显著降低术后远期复发率,可能与纳米粒治疗能够降低患者VEGF水平有关。

关键词: 经导管肝动脉化疗栓塞, 纳米粒, 早期肝癌, 门静脉高压, 安全性

Abstract: Objective To investigate the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with nanoparticles in the treatment of early-stage liver cancer complicated by portal hypertension.Methods Ninety-eight patients with early-stage liver cancer complicated by portal hypertension treated in our hospital from February 2013 to January 2018 were selected and divided into TACE group (45 cases) and combination therapy group (TACE combined with nanoparticle therapy, 53 cases). The efficacy of treatment, cancer recurrence rate and postoperative complication rate were compared between the 2 groups. The liver function and tumor factor indexes were compared before and 1 month after surgery in the 2 groups.Results (1) The Objective response rate (ORR) and disease control rate (DCR) were 58.49% and 86.79% in combination therapy group, 55.56% and 84.44% in TACE group, respectively. There was no statistical difference between the 2 groups (P>0.05). (2) There was no statistical difference in the levels of alanine aminotransferase or aspartate aminotransferase between the 2 groups before or 1 month after surgery (P>0.05). (3) There was no significant difference in carcinoembryonic antigen levels before or 1 month after surgery between the 2 groups (P>0.05). The level of vascular endothelial growth factor (VEGF) 1 month after surgery in combination therapy group was lower than that in TACE group (P<0.05). (4) The recurrence rates at 1 and 2 years after surgery in combination therapy group were lower than those in TACE group (P<0.05). (5) There was no significant difference in the rate of postoperative complications between the 2 groups (P>0.05).Conclusion TACE has good therapeutic effect on the early-stage liver cancer complicated by portal hypertension. Besides, nanoparticle therapy can significantly reduce the long-term recurrence rate after surgery. The reason may be that nanoparticle therapy can reduce the VEGF level in patients.

Key words: Transarterial chemoembolization, Nanoparticles, Early-stage liver cancer, Portal hypertension, Safety

房启楼, 倪建勋, 范红星, 金戈. TACE联合纳米粒治疗早期肝癌并发门静脉高压的疗效及安全性[J]. 肝脏, 2021, 26(1): 51-54.

FANG Qi-lou, NI Jian-xun, FAN Hong-xing, JIN Ge. Efficacy and safety of TACE and nanoparticles in the treatment of portal hypertension in early-stage liver cancer[J]. Chinese Hepatolgy, 2021, 26(1): 51-54.

参考文献

[1] 魏矿荣,彭侠彪,梁智恒,等.全球肝癌流行概况.中国肿瘤,2015,24:621-630.
[2] 格桑旺姆, 常中飞, 杜雅璐, 等. 2001-2017年我院原发性肝癌流行病学特征分析. 中华介入放射学电子杂志, 2019, 7:206-210.
[3] 李爱军,马森林,吴孟超.分子靶向药物在肝癌治疗中的作用.肝胆胰外科杂志,2015,27: 255-258+261.
[4] 王波,钱叶本,罗雪莲, 等.肝癌复发的诊断与治疗进展.肝胆外科杂志,2016,24: 307-312.
[5] 柏斗胜,赵伟,蒋国庆, 等.同步腹腔镜肝切除联合脾切除术治疗原发性肝癌并发肝硬化门静脉高压性脾功能亢进.中华消化外科杂志,2015,14:750-754.
[6] 李文华,刘晓红,朱国艳, 等.N-乙酰半胱氨酸对TACE肝癌患者凝血酶原、胆红素和谷丙转氨酶的影响.肝脏,2019,24:294-296.
[7] 梅朝蓉,雷娜,徐静,等.231例西藏地区藏族原发性肝癌的临床特征分析.齐齐哈尔医学院学报,2018,39:384-387.
[8] 徐小元,丁惠国,贾继东,等.肝硬化门静脉高压食管胃静脉曲张出血防治指南(2015).中华胃肠内镜电子杂志,2015,2:1-21.
[9] 赵连晖,贾继东.应重视门静脉高压症的病因诊断及规范治疗.临床肝胆病杂志,2019,35:12-14.
[10] 刘桂勤,华静,沈加林.CT门静脉血管成像预测肝硬化门静脉高压食管胃底静脉曲张破裂出血价值.中华实用诊断与治疗杂志,2015,29:396-398.
[11] 陈建武. 腹腔镜下肝切除联合选择性断流术治疗原发性肝细胞癌合并门静脉高压临床疗效观察. 医学临床研究, 2018, 35:1224-1227.
[12] 甘雨, 田娜娜, 陈华辉, 等.原发性肝癌患者AFP浓度与临床特点及预后的相关性. 中华肿瘤防治杂志, 2016, 23:958-962.
[13] 王茹, 杨晓莹, 王克英, 等. 纹理分析对经动脉化学栓塞治疗术后肝癌复发的评价. 中华肝脏病杂志, 2017,25:200-204.
[14] 刘志强, 王湘毅, 孙晓革, 等. CA125,CA153及CEA肿瘤标志物联合检测对非小细胞肺癌早期诊断的临床意义. 临床合理用药杂志, 2016, 9:111-112.
[15] 方世记, 郑丽云, 程适妙, 等. TACE联合RFA治疗中晚期肝癌后早期复发相关危险因素研究. 中华介入放射学电子杂志, 2019, 7:106-110.